NCT05750719 (Light-Bright) is a clinical trial of BRCA1/2 genetic testing in Triple-Negative Breast Cancer, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Who is sponsoring NCT05750719?

NCT05750719 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

What drugs are being tested in NCT05750719?

Interventions in NCT05750719: BRCA1/2 genetic testing.

What condition does NCT05750719 study?

NCT05750719 studies Triple-Negative Breast Cancer.

Is NCT05750719 still recruiting?

NCT05750719 is currently completed. Last updated 2 March 2023.

Last reviewed 2023-03-02 · How we verify

NCT05750719: Light-Bright

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BRCA and NACT in TNBC Patients

Completed Last updated 2 March 2023

What this trial tests

trial testing BRCA1/2 genetic testing in Triple-Negative Breast Cancer in 136 participants. Completed in 1 October 2022.

Timeline

2 January 2013

Primary endpoint
1 October 2022

1 October 2022

Quick facts

Lead sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Status	Completed
Study type	OBSERVATIONAL
Enrollment	136
Start date	2 January 2013
Primary completion	1 October 2022
Estimated completion	1 October 2022
Sites	1 location across Italy

Drugs / interventions tested

BRCA1/2 genetic testing

Conditions studied

Triple-Negative Breast Cancer — all drugs for Triple-Negative Breast Cancer →

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, female only, with Triple-Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to evaluate data from patients with triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT) in order to better define the impact of germline BRCA1/2 (gBRCA1/2) mutation status on outcomes in this patient population. The aims of the study are: * To evaluate the rate of pathologic complete response (pCR) in patients with locally advanced TNBC who performed NACT, in relation to the mutational status of gBRCA. * To evaluate Evaluate Event Free survival (EFS) and Overall Survival (OS) in this patients population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Triple-Negative Breast Cancer

Currently open trials in the same condition.

NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Pa · NA · recruiting
NCT07104266 — Triple Negative Breast Cancer and Celecoxib. Pilot Study · Phase 2 · recruiting
NCT06393374 — Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · Phase 3 · recruiting
NCT05806060 — Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer · Phase 3 · recruiting
NCT05760378 — Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or M · Phase 3 · recruiting

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05750719 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Last refreshed: 2 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05750719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing